Predictive Oncology Inc. (POAI) News
Filter POAI News Items
POAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
POAI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest POAI News From Around the Web
Below are the latest news stories about PREDICTIVE ONCOLOGY INC that investors may wish to consider to help them evaluate POAI as an investment opportunity.
Renovaro Issues Shareholder Letter and Provides Corporate UpdateCompany to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive anal |
Renovaro to Acquire Predictive Oncology in All-Stock TransactionAcquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug disco |
Predictive Oncology Announces Agreement to be Acquired by Renovaro- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders’ interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has entered into a binding letter of intent with Renovaro, I |
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic AlternativesPITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024. As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including a potential sale of the Company, a sale of one or more assets of the Company, a merger, licensing agreement, or other strat |
Predictive Oncology Third Quarter 2024 Earnings: Misses ExpectationsPredictive Oncology ( NASDAQ:POAI ) Third Quarter 2024 Results Key Financial Results Revenue: US$345.7k (down 52% from... |
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic UpdateCompany initiates process to explore a broad range of strategic alternatives to maximize shareholder valuePITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended S |
Predictive Oncology Inc (POAI) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst ...Despite a decline in revenue, Predictive Oncology Inc (POAI) strengthens its AI capabilities and financial position through strategic initiatives and collaborations. |
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY. Management’s presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. The Predicti |
Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug DiscoveryStudy further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples Global biospecimen market valued at $4.4 billion in 2023, expected to grow at an annual CAGR of more than 13%, reaching $11.7 billion by 20311 PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced the results of a successful study that demonstrates the long-term stabil |
Predictive Oncology Inc. (NASDAQ:POAI) Is Expected To Breakeven In The Near FutureWe feel now is a pretty good time to analyse Predictive Oncology Inc.'s ( NASDAQ:POAI ) business as it appears the... |